NCT06178926

Ciprofol Sedation in Patients Undergoing Liver Cancer Percutaneous Radiofrequency Ablation

Efficacy and Safety of Ciprofol Sedation in Patients Undergoing Liver Cancer Percutaneous Radiofrequency Ablation: A Double-Blind, Randomized, Noninferiority Trial

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Zhejiang Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Efficacy and Safety of Ciprofol Sedation in Patients Undergoing Liver Cancer Percutaneous Radiofrequency Ablation

Detailed description

Ciprofol was injected before ablation and sedation scores were measured to make sure certain sedation.

Conditions

• Liver Cancer
• Ciprofol

Interventions

Type	Name	Description
DRUG	Propofol	Propofol was IV infused 1.0-1.5mg/Kg and then maintenance at 1.0-2.0mg/Kg/h
DRUG	Ciprofol	Ciprofol was IV infused 0.2- 0.3mg/Kg and then maintenance at 0.2-0.3mg/Kg/h

Timeline

• Start date: 2023-08-01
• Primary completion: 2024-12-30
• Completion: 2024-12-30
• First posted: 2023-12-21
• Last updated: 2023-12-21

Locations

1 site across 1 country: China